Regeneron ONYX AMD-1517

Status: Ongoing, but not recruiting participants.

ClinicalTrials.gov Identifier: NCT02713204

Regeneron Onyx: A randomized, double masked, active controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular AMD.

Condition: Neovascular Age-Related Macular Degeneration

Study Type: Interventional

Duration: 36 weeks

Eligibility:

  • Ages: 50 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.